Bidstrup B P, Harrison J, Royston D, Taylor K M, Treasure T
Cardiothoracic Unit, Wellington Hospital, London, United Kingdom.
Ann Thorac Surg. 1993 Apr;55(4):971-6. doi: 10.1016/0003-4975(93)90128-5.
Aprotinin, a serine protease inhibitor, has recently been shown to reduce blood loss in cardiac surgical patients. Data on the safety and efficacy of aprotinin therapy administered to 671 cardiac surgical patients in 41 United Kingdom cardiac surgical units have been submitted to interim analysis. The patients studied were in high-risk categories for excessive bleeding, including 457 redo operations and 79 patients with active infective endocarditis. Overall mortality was 12% in redo cases and 5.1% in first-time operations. Adverse events were reported in only 20 patients (3%). Median blood loss at 24 hours after operation was 400 mL, and median transfusion volume throughout the operative and postoperative period was 2 units. These data confirm that the use of aprotinin therapy in high-risk cardiac surgical patients is associated with a low incidence of adverse events.
抑肽酶是一种丝氨酸蛋白酶抑制剂，最近已被证明可减少心脏手术患者的失血量。在英国41个心脏外科单位对671名心脏手术患者进行抑肽酶治疗的安全性和有效性数据已提交进行中期分析。所研究的患者属于出血过多的高危类别，包括457例再次手术患者和79例活动性感染性心内膜炎患者。再次手术病例的总死亡率为12%，初次手术患者为5.1%。仅20例患者（3%）报告了不良事件。术后24小时的中位失血量为400毫升，整个手术和术后期间的中位输血量为2个单位。这些数据证实，在高危心脏手术患者中使用抑肽酶治疗与不良事件发生率低相关。
